Related references
Note: Only part of the references are listed.HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer
S. F. Schoppmann et al.
ANNALS OF ONCOLOGY (2010)
Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review
Giuseppe Curigliano et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2010)
Cardiotoxicity induced by tyrosine kinase inhibitors
George S. Orphanos et al.
ACTA ONCOLOGICA (2009)
HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
Dorte Lisbet Nielsen et al.
CANCER TREATMENT REVIEWS (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Bevacizumab - In first-line treatment of metastatic breast cancer
Lesley J. Scott
DRUGS (2007)
HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy
X-F Wen et al.
ONCOGENE (2006)
Pathophysiological consequences of VEGF-induced vascular permeability
SM Weis et al.
NATURE (2005)
ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter
RMB Loureiro et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients
GE Konecny et al.
CLINICAL CANCER RESEARCH (2004)
In vitro effects of trastuzumab and vinorelbine in trastuzumab-resistant breast cancer cells
R Nahta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment
B Linderholm et al.
EUROPEAN JOURNAL OF CANCER (2004)
Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer
H Burris et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Pharmacokinetics and biodistribution of genetically engineered antibodies
SK Batra et al.
CURRENT OPINION IN BIOTECHNOLOGY (2002)
Neutralising human recombinant antibodies to human cytomegalovirus glycoproteins gB and gH
F Nejatollahi et al.
FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY (2002)
Differential regulation of tumor angiogenesis by distinct ErbB homo- and heterodimers
L Yen et al.
MOLECULAR BIOLOGY OF THE CELL (2002)
Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells
GP Pidgeon et al.
BRITISH JOURNAL OF CANCER (2001)
Molecular mechanisms underlying ErbB2/HER2 action in breast cancer
D Harari et al.
ONCOGENE (2000)
Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis
L Yen et al.
ONCOGENE (2000)
Share Paper
